secwatch.observer — SEC 8-K summary
======================================

Issuer:     Journey Medical Corp (DERM)
CIK:        0001867066
Form:       8-K
Filed at:   2022-01-13T23:59:59+00:00
Accession:  0001104659-22-003789
Event type: m_and_a
Sentiment:  positive
Materiality: 0.75
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Journey Medical acquires VYNE's MST franchise for $20M upfront; credit facility expanded to $30M
--------------------------------------------------------------------------------

- Acquired AMZEEQ, ZILXI, FCD105, and MST platform for $20M upfront plus $5M at one year; contingent milestones up to $450M.
- Products generated ~$4M net sales in Q3 2021; portfolio now includes nine marketed dermatology products.
- Credit facility with East West Bank expanded to $30M: $10M revolver + $20M term loan to finance acquisition and working capital.
- Journey substituted as plaintiff in patent litigation against Padagis over Amzeeq; trial set for July 2023, stay until Dec 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1867066/000110465922003789/0001104659-22-003789-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1867066/000110465922003789/tm222871d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-22-003789

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer